Lifesci Capital Upgrades Larimar Therapeutics (NASDAQ:LRMR) to “Strong-Buy”

Larimar Therapeutics (NASDAQ:LRMR) was upgraded by research analysts at Lifesci Capital to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

LRMR has been the subject of several other research reports. Leerink Partners upgraded Larimar Therapeutics to a “strong-buy” rating in a report on Monday, January 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $16.14.

Larimar Therapeutics Trading Up 61.2%

Larimar Therapeutics stock opened at $5.95 on Tuesday. Larimar Therapeutics has a 1-year low of $1.61 and a 1-year high of $6.42. The company has a fifty day simple moving average of $3.49 and a 200 day simple moving average of $3.77. The company has a market cap of $492.54 million, a P/E ratio of -3.08 and a beta of 1.00.

Hedge Funds Weigh In On Larimar Therapeutics

Several institutional investors have recently bought and sold shares of the company. CWM LLC increased its position in Larimar Therapeutics by 10.3% in the third quarter. CWM LLC now owns 36,013 shares of the company’s stock worth $116,000 after buying an additional 3,361 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Larimar Therapeutics by 75.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock worth $33,000 after acquiring an additional 4,376 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in shares of Larimar Therapeutics by 33.9% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 18,248 shares of the company’s stock worth $59,000 after acquiring an additional 4,619 shares during the period. Velan Capital Investment Management LP increased its holdings in Larimar Therapeutics by 17.9% in the 2nd quarter. Velan Capital Investment Management LP now owns 33,000 shares of the company’s stock worth $95,000 after acquiring an additional 5,000 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in Larimar Therapeutics by 7.8% in the 2nd quarter. American Century Companies Inc. now owns 69,285 shares of the company’s stock worth $200,000 after acquiring an additional 5,001 shares during the last quarter. Hedge funds and other institutional investors own 91.92% of the company’s stock.

Key Larimar Therapeutics News

Here are the key news stories impacting Larimar Therapeutics this week:

• Positive Sentiment: FDA granted Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia, management reiterated a planned BLA submission in June 2026 and target U.S. launch in H1 2027 if approved — a development that materially de-risks the program and supports accelerated approval prospects. Article Title
• Positive Sentiment: Several analysts upgraded or raised price targets (Citigroup to $14 buy, Wedbush reaffirmed outperform with $11 PT, Lifesci Capital to strong-buy), signaling institutional bullishness that can support upside momentum. Article Title
• Neutral Sentiment: Unusual options activity: traders bought ~3,744 calls (≈456% above typical daily call volume), indicating speculative/leveraged bullish positioning that may amplify intraday moves but is not a fundamental change.
• Neutral Sentiment: Media coverage and headlines about the FDA action drove a sharp pre-market surge and massive intraday trading volume (recent reports show daily volume far above the stock’s average), increasing volatility and short-term liquidity. Article Title
• Negative Sentiment: Larimar filed a proposed underwritten public offering of $75 million of common stock (with an underwriter option for an additional $11.25M) — a sizable raise relative to its market cap that introduces near-term dilution risk and can pressure the share price until proceeds are deployed. The offering is subject to market conditions and may create volatility. Article Title

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.